Skip Navigation
Leading research to understand, treat, and prevent infectious, immunologic, and allergic diseases
NIH HHS News Release Logo
National Institute of Allergy and
Infectious Diseases (NIAID)

April 7, 2014

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

NIH Funding Opportunity Focuses on Diagnostics for Hospital-Based Antibacterial-Resistant Infections

Awards to Total up to $12 Million in 2015

​The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, recently announced a research funding opportunity to develop and/or produce diagnostics to quickly detect the key bacteria responsible for antibacterial-resistant infections in hospital settings. NIAID expects to fund 10-15 awards for a total of up to $12 million in 2015. The maximum length of each award is 5 years.
Drug-resistant bacterial infections are a growing worldwide problem, causing significant illness, death and healthcare cost. Many of these infections are acquired in hospitals and other healthcare settings, where rapid and sensitive testing for specific types of bacteria are needed to enable physicians to determine the most effective treatments to improve individual patient outcomes and help curb bacterial resistance.
The new request for applications (RFA), called “Partnerships for Diagnostics to Address Antimicrobial Resistance of Select Bacterial Pathogens,” will support diagnostics research related to one or more of the following five types of bacteria commonly responsible for antibacterial-resistant infections in hospitals: Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species, and extra-intestinal pathogenic Eschericihia coli.
Investigators from academic organizations are eligible to submit proposals, but must establish a partnership with an industrial organization. Applications submitted by industrial institutions or non-profit product development agencies do not require an additional partner.
NIAID will accept applications through June 19, 2014. View the complete RFA (RFA-AI-14-019).

NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit

NIH...Turning Discovery Into Health ®

back to top

Last Updated April 04, 2014

Last Reviewed April 04, 2014